FDA Approves Innovative Treatment for KRAS G12C-Colorectal Cancer, Offering Hope for Patients Amgen has achieved FDA approval for LUMAKRAS combined with Vectibix to treat metastatic colorectal cancer with KRAS G12C mutation, enhancing patient outcomes significantly.

FDA Approves Innovative Treatment for KRAS G12C-Colorectal Cancer, Offering Hope for Patients #United_States #Thousand_Oaks #KRAS_G12C #Vectibix #LUMAKRAS